Table 6.

Overall and Location-specific Usage of Orthobiologics in the Treatment of Labral Injuries

Labral Injury–specific Users	PRP-LR, 70.6% (n = 77)	PRP-LP, 76.1% (n = 83)	BMAC, 44.0% (n = 48)	AMP, 24.8% (n = 27)	Ad-MSC, 15.6% (n = 17)	UCD, 6.4% (n = 7)
Overall, 11.9% (n = 13)
Nonsurgical, 8.3% (n = 9)	6.5% (n = 5)	6.0% (n = 5)	8.3% (n = 4)	7.4% (n = 2)	5.9% (n = 1)	0.0% (n = 0)
Nonsurgical location
Hip	20.0%	20.0%	50.0%	100.0%	100.0%	—
Shoulder	80.0%	80.0%	100.0%	50.0%	100.0%	—
Surgical, 10.1% (n = 11)	6.5% (n = 5)	6.0% (n = 5)	8.3% (n = 4)	7.4% (n = 2)	5.9% (n = 1)	0.0% (n = 0)
Surgical location
Hip	0%	0%	25.0%	50.0%	100.0%	—
Shoulder	100%	100%	100.0%	100.0%	100.0%	—

Ad-MSC = adipose-derived mesenchymal stromal cells, AMP = amniotic membrane products, BMAC = bone marrow aspirate concentrate, PRP-LP = leukocyte-poor platelet-rich plasma, PRP-LR = leukocyte-rich platelet-rich plasma, UCD = umbilical cord–derived cells

Percentages in the top row and left-most column represent proportions with respect to all 109 users of any orthobiologics. Percentages throughout the rest of the table represent proportions with respect to the “n” value nearest vertically in the table. Specifically, percentages in the nonsurgical and surgical rows represent proportions with respect to all users of the orthobiologic indicated at the top of each column. Percentages in the rows below nonsurgical location and surgical location represent proportions with respect to all users of the column's specific orthobiologic in the indicated setting of nonsurgical or surgical.